Ansbert Gadicke Sells 57,061 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Ansbert Gadicke sold 57,061 shares of the firm’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $0.95, for a total transaction of $54,207.95. Following the completion of the transaction, the insider owned 5,481,539 shares of the company’s stock, valued at approximately $5,207,462.05. The trade was a 1.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Ansbert Gadicke also recently made the following trade(s):

• On Friday, November 14th, Ansbert Gadicke sold 61,640 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.93, for a total transaction of $57,325.20.
• On Thursday, November 13th, Ansbert Gadicke sold 90,951 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.98, for a total transaction of $89,131.98.
• On Wednesday, November 12th, Ansbert Gadicke sold 40,669 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.09, for a total transaction of $44,329.21.
• On Tuesday, November 11th, Ansbert Gadicke sold 55,810 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.14, for a total value of $63,623.40.
• On Monday, November 10th, Ansbert Gadicke sold 48,570 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.18, for a total value of $57,312.60.
• On Friday, November 7th, Ansbert Gadicke sold 68,480 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.11, for a total value of $76,012.80.
• On Thursday, November 6th, Ansbert Gadicke sold 54,452 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.21, for a total value of $65,886.92.
• On Wednesday, November 5th, Ansbert Gadicke sold 47,950 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.22, for a total value of $58,499.00.
• On Tuesday, November 4th, Ansbert Gadicke sold 140,488 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.22, for a total value of $171,395.36.
• On Monday, November 3rd, Ansbert Gadicke sold 94,063 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.29, for a total value of $121,341.27.

Werewolf Therapeutics Stock Up 0.1%

Shares of NASDAQ HOWL traded up $0.00 during mid-day trading on Monday, reaching $0.92. The company had a trading volume of 519,418 shares, compared to its average volume of 503,244. Werewolf Therapeutics, Inc. has a 12-month low of $0.60 and a 12-month high of $2.38. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.87 and a current ratio of 3.87. The company has a market capitalization of $44.63 million, a price-to-earnings ratio of -0.57 and a beta of 0.72. The stock has a fifty day moving average of $1.57 and a two-hundred day moving average of $1.34.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.03. As a group, equities research analysts expect that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have commented on HOWL shares. Citigroup restated a “market outperform” rating on shares of Werewolf Therapeutics in a research note on Wednesday, November 12th. JMP Securities reduced their target price on shares of Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a research note on Thursday, August 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Wednesday, October 8th. Zacks Research upgraded shares of Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 16th. Finally, Bank of America decreased their price objective on shares of Werewolf Therapeutics from $9.00 to $8.00 and set a “buy” rating for the company in a report on Monday, August 25th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $8.00.

Institutional Trading of Werewolf Therapeutics

Several institutional investors have recently modified their holdings of HOWL. Susquehanna International Group LLP raised its holdings in shares of Werewolf Therapeutics by 16.9% in the 3rd quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock worth $183,000 after buying an additional 13,439 shares in the last quarter. Citadel Advisors LLC acquired a new position in Werewolf Therapeutics in the third quarter valued at about $304,000. Vanguard Group Inc. boosted its position in shares of Werewolf Therapeutics by 8.5% during the third quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock worth $2,774,000 after purchasing an additional 109,796 shares in the last quarter. Bridgeway Capital Management LLC grew its stake in Werewolf Therapeutics by 157.7% in the second quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock valued at $111,000 after acquiring an additional 62,414 shares during the period. Finally, Bank of America Corp DE raised its holdings in Werewolf Therapeutics by 1.2% during the 2nd quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock worth $2,321,000 after buying an additional 25,882 shares during the period. Institutional investors and hedge funds own 64.84% of the company’s stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.